Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PRD004
MIFTS: 47

Prediabetes Syndrome

Categories: Blood diseases, Metabolic diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Prediabetes Syndrome

About this section

MalaCards integrated aliases for Prediabetes Syndrome:

Name: Prediabetes Syndrome 12 15 17 71
Prediabetic State 12 54 43
Prediabetes 12 42 15

Classifications:

MalaCards categories:
Global: Metabolic diseases
Anatomical: Blood diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:11716
MeSH 43 D011236
NCIt 49 C122685
SNOMED-CT 67 714628002
ICD10 32 R73.03
UMLS 71 C0362046
Sources

Summaries for Prediabetes Syndrome

About this section
MedlinePlus : 42 What is prediabetes? Prediabetes means that your blood glucose, or blood sugar, levels are higher than normal but not high enough to be called diabetes. Glucose comes from the foods you eat. Too much glucose in your blood can damage your body over time. If you have prediabetes, you are more likely to develop type 2 diabetes, heart disease, and stroke. But if you make some lifestyle changes now, you may be able to delay or prevent type 2 diabetes. What causes prediabetes? Prediabetes usually happens when your body has a problem with insulin. Insulin is a hormone that helps the glucose get into your cells to give them energy. A problem with insulin could be Insulin resistance, a condition in which the body can't use its insulin properly. It makes it hard for your cells to get glucose from your blood. This can cause your blood sugar levels to rise. Your body can't make enough insulin to keep your blood sugar levels at a healthy level Researchers think that being overweight and not getting regular physical activity are major factors in causing prediabetes. Who is at risk for prediabetes? About 1 out of every 3 adults has prediabetes. It is more common in people who Are overweight or have obesity Are age 45 or older Have a parent, brother, or sister with diabetes Are African American, Alaska Native, American Indian, Asian American, Hispanic/Latino, Native Hawaiian, or Pacific Islander American Are not physically active Have health conditions such as high blood pressure and high cholesterol Have had gestational diabetes (diabetes in pregnancy) Have a history of heart disease or stroke Have metabolic syndrome Have polycystic ovary syndrome (PCOS) What are the symptoms of prediabetes? Most people don't know they have prediabetes because usually there are no symptoms. Some people with prediabetes may have darkened skin in the armpit or on the back and sides of the neck. They may also have many small skin growths in those same areas. How is prediabetes diagnosed? There are a few different blood tests that can diagnose prediabetes. The most common ones are Fasting plasma glucose (FPG) test, which measures your blood sugar at a single point in time. You need to fast (not eat or drink) for at least 8 hours before the test. The results of the test are given in mg/dL (milligrams per deciliter): A normal level is 99 or below Prediabetes is 100 to 125 Type 2 diabetes is 126 and above A1C test, which measures your average blood sugar over the past 3 months. The results of an A1C test are given as a percentage. The higher the percentage, the higher your blood sugar levels have been. A normal level is below 5.7 percent Prediabetes is between 5.7 to 6.4 percent Type 2 diabetes is above 6.5 percent If I have prediabetes, will I get diabetes? If you have prediabetes, you may be able to delay or prevent type 2 diabetes through lifestyle changes: Losing weight, if you are overweight Getting regular physical activity Following a healthy, reduced-calorie eating plan In some cases, your health care provider may also recommend taking diabetes medicines. Can prediabetes be prevented? If you are at risk for prediabetes, those same lifestyle changes (losing weight, regular physical activity, and a healthy eating plan) may prevent you from getting it. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Prediabetes Syndrome, also known as prediabetic state, is related to polycystic ovary syndrome and non-alcoholic steatohepatitis. An important gene associated with Prediabetes Syndrome is INS (Insulin), and among its related pathways/superpathways are Common Cytokine Receptor Gamma-Chain Family Signaling Pathways and AMP-activated Protein Kinase (AMPK) Signaling. The drugs tannic acid and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and liver, and related phenotypes are endocrine/exocrine gland and homeostasis/metabolism

Wikipedia : 74 Prediabetes is a component of the metabolic syndrome and is characterized by elevated blood sugar levels... more...

Sources

Related Diseases for Prediabetes Syndrome

About this section

Diseases related to Prediabetes Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 544)
# Related Disease Score Top Affiliating Genes
1 polycystic ovary syndrome 33.0 PPARG LEP INS CRP ADIPOQ
2 non-alcoholic steatohepatitis 32.8 SLC2A4 PPARG INS IL6 ALB ADIPOQ
3 fatty liver disease 32.7 PPARG LEP INS IL6 CRP ALB
4 diabetes mellitus 31.7 SLC2A4 PPARG MIR144 MIR126 LEP INS
5 fatty liver disease, nonalcoholic 1 31.4 LEP INS ADIPOQ
6 acute insulin response 31.4 INS GCG CRP
7 lipid metabolism disorder 31.3 PPARG MIR126 LEP INS IL6 CRP
8 hyperinsulinism 31.2 SLC2A4 PPARG LEP INS HK1 GCG
9 hypercholesterolemia, familial, 1 31.2 INS CRP COG2
10 hyperglycemia 31.1 SLC2A4 PPARG MIR126 LEP INS IL6
11 liver disease 31.1 SERPINA3 LEP INS IL6 ALB ADIPOQ
12 autoimmune disease 31.1 INS IL6 GAD1 DPP4 CRP
13 polyneuropathy 31.1 INS IL6 CRP ALB
14 coronary heart disease 1 31.1 MIR126 INS IL6 CRP COG2 ADIPOQ
15 lipoprotein quantitative trait locus 31.0 MIR126 IL6 CRP COG2 ALB
16 hyperuricemia 31.0 PPARG LEP INS CRP ALB
17 acute pancreatitis 30.9 SERPINA3 INS IL6 CRP ALB
18 autonomic neuropathy 30.9 INS GCG ALB
19 atherosclerosis susceptibility 30.8 PPARG LEP INS IL6 CRP COG2
20 sexual disorder 30.8 SERPINA3 INS ALB
21 acanthosis nigricans 30.8 SLC2A4 PPARG LEP INS ADIPOQ
22 gestational diabetes 30.8 SLC2A4 PPARG LEP INS IL6 GCG
23 peripheral vascular disease 30.8 INS IL6 CRP COG2 ALB
24 chronic kidney disease 30.8 SERPINA3 LEP INS IL6 CRP ALB
25 end stage renal disease 30.7 INS IL6 CRP ALB ADIPOQ
26 pancreatitis 30.7 INS IL6 GCG CRP ALB
27 congestive heart failure 30.7 INS IL6 CRP ALB
28 sleep apnea 30.7 PPARG LEP INS IL6 CRP ALB
29 macular retinal edema 30.7 INS IL6 ALB
30 angina pectoris 30.6 INS IL6 CRP ADIPOQ
31 deficiency anemia 30.6 INS IL6 CRP ALB
32 arteriosclerosis 30.6 PPARG MIR126 INS IL6 CRP COG2
33 hypothyroidism 30.6 LEP INS CRP COG2 ALB ADIPOQ
34 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 30.6 LEP INS ADIPOQ
35 proteasome-associated autoinflammatory syndrome 1 30.6 PPARG IL6 CRP ADIPOQ
36 anxiety 30.6 INS IL6 GAD1 CRP
37 acute myocardial infarction 30.6 SERPINA3 MIR486-1 MIR126 IL6 CRP
38 stroke, ischemic 30.5 SERPINA3 IL6 CRP COG2 ALB
39 silent myocardial infarction 30.5 INS CRP COG2
40 coronary stenosis 30.5 IL6 CRP ALB ADIPOQ
41 non-alcoholic fatty liver disease 30.5 SLC2A4 PPARG MIR126 LEP INS IL6
42 vascular disease 30.5 PPARG MIR126 LEP INS IL6 CRP
43 placenta disease 30.5 SERPINA3 INS IL6 CRP ADIPOQ
44 sleep disorder 30.5 LEP INS IL6 CRP ADIPOQ
45 kwashiorkor 30.5 INS CRP ALB
46 pulmonary tuberculosis 30.5 MIR144 IL6 CRP ALB
47 mental depression 30.5 SERPINA3 MIR144 IL6 DPP4 CRP
48 cerebrovascular disease 30.5 SERPINA3 LEP INS IL6 CRP ADIPOQ
49 anovulation 30.5 LEP INS CRP
50 peripheral nervous system disease 30.5 SERPINA3 MIR144 MIR126 LEP INS IL6

Graphical network of the top 20 diseases related to Prediabetes Syndrome:



Diseases related to Prediabetes Syndrome
Sources

Symptoms & Phenotypes for Prediabetes Syndrome

About this section

MGI Mouse Phenotypes related to Prediabetes Syndrome:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.81 ADIPOQ ALB DPP4 GAD1 IL6 INS
2 homeostasis/metabolism MP:0005376 9.77 ADIPOQ ALB COG2 CRP DPP4 GAD1
3 liver/biliary system MP:0005370 9.23 ADIPOQ ALB HK1 IL6 INS LEP
Sources

Drugs & Therapeutics for Prediabetes Syndrome

About this section

Drugs for Prediabetes Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 354)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
tannic acid Approved Phase 4 1401-55-4
2
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
3
Insulin glargine Approved Phase 4 160337-95-1
4
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
5
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
6
Phylloquinone Approved, Investigational Phase 4 84-80-0
7
Saxagliptin Approved Phase 4 361442-04-8 11243969
8
Pravastatin Approved Phase 4 81093-37-0 54687
9
Bilberry Approved, Experimental Phase 4
10
Nitric Oxide Approved Phase 4 10102-43-9 145068
11
Hydroxychloroquine Approved Phase 4 118-42-3 3652
12
Atorvastatin Approved Phase 4 134523-00-5 60823
13
Pitavastatin Approved Phase 4 147526-32-7, 147511-69-1 6366718 5282452
14
Liraglutide Approved Phase 4 204656-20-2 44147092
15
Curcumin Approved, Experimental, Investigational Phase 4 458-37-7 969516
16
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
17
Amlodipine Approved Phase 4 88150-42-9 2162
18
Fluspirilene Approved, Investigational Phase 4 1841-19-6 3396
19
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605
20
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
21
Dulaglutide Approved, Investigational Phase 4 923950-08-7
22
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 11953898
23
Canagliflozin Approved Phase 4 842133-18-0
24
Ethanol Approved Phase 4 64-17-5 702
25
Glucagon Approved Phase 4 16941-32-5
26
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
27
Sodium citrate Approved, Investigational Phase 4 68-04-2
28
Menadione Approved, Nutraceutical Phase 4 58-27-5 4055
29
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
30
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
31
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
32 Menaquinone Investigational Phase 4 1182-68-9
33
Menatetrenone Investigational Phase 4 863-61-6 5282367
34
Voglibose Investigational Phase 4 83480-29-9 444020
35
Cobalamin Experimental Phase 4 13408-78-1 6857388
36 naphthoquinone Phase 4
37 Vitamin K Phase 4
38 Hemostatics Phase 4
39 Coagulants Phase 4
40 Anthocyanidin Phase 4
41 Alpha-lipoic Acid Phase 4
42 Thioctic Acid Phase 4
43 Biguanides Phase 4
44 Cardiac Glycosides Phase 4
45 Glycoside Hydrolase Inhibitors Phase 4
46 Glucagon-Like Peptide 1 Phase 4
47 Dipeptidyl-Peptidase IV Inhibitors Phase 4
48 Sitagliptin Phosphate Phase 4
49 HIV Protease Inhibitors Phase 4
50
protease inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 783)
# Name Status NCT ID Phase Drugs
1 Intensity of Exercise and Glucose Metabolism Unknown status NCT01649219 Phase 4
2 Effect of Saxagliptin on Body Fat , Glucose and Beta Cell Function in Patients With Newly Diagnosed Pre-Diabetes Mellitus and Obesity Unknown status NCT01960205 Phase 4 Saxagliptin;saxagliptin;metformin
3 Antiatherogenic and Antimetabolic Effect of Curcumin Therapy in the Prevention and Delay of Type 2 Diabetic in Patients With Impaired Glucose Tolerance and Insulin Resistance Unknown status NCT01052025 Phase 4 Curcumin
4 Healthy Heart Study: Can Insulin Glargine Improve Myocardial Function in Patients With Type 2 Diabetes and Coronary Artery Disease? A Prospective, Randomized, Controlled Clinical Study With Blinded Analysis of Ultrasound Data Unknown status NCT01035528 Phase 4 insulin glargine;metformin
5 Insulin Resistance and Mild Cognitive Impairment (MCI) in Older Chinese Adults With Pre-Diabetes and Diabetes: Cognitive Effects of Lifestyle Intervention and Metformin Treatment in a Randomized Controlled Trial Unknown status NCT02409238 Phase 4 Metformin
6 Effect of Rubus Occidentalis Extract on Plasma Glucose Levels in Subject With Prediabetes; A Proof-of-concept, Randomized, Double-blind, Parallel-group Placebo-controlled Study Completed NCT01964703 Phase 4 Rubus occidentalis extract
7 Effects of Physical Exercise Versus Rosiglitazone on Endothelial Function in Coronary Artery Disease Patients With Prediabetes Completed NCT00675740 Phase 4 rosiglitazone
8 Jom Mama Project - Pre-pregnancy Intervention to Reduce the Risk of Diabetes and Prediabetes Completed NCT02617693 Phase 4
9 Oral Cholecalciferol in Prevention of Type 2 DM in Prediabetic Population With Vitamin D Insufficiency Completed NCT01436916 Phase 4 oral cholecalciferol + life style counselling;placebo + life style counselling
10 Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes Completed NCT02700334 Phase 4 Dapagliflozin;Placebo
11 Effect of Dapagliflozin on Blood Pressure Variability in Patients With Prediabetes and Prehypertension Without Pharmacological Treatment Completed NCT03006471 Phase 4 Dapagliflozin;Placebo - Cap
12 Effect of Linagliptin + Metformin on Glucose Metabolism and Pancreatic Beta Cell Function in Patients With Prediabetes Who do Not Achieve Normoglycemia After 12 Months of Treatment With Metformin Alone Completed NCT04088461 Phase 4 Linagliptin / Metformin Oral Tablet;Metformin
13 Effect of Pravastatin in the Subjects With Prediabetes or Early Diabetes Completed NCT02754739 Phase 4 Pravastatin;Placebo (for Pravastatin)
14 Effect of Linagliptin + Metformin vs Metformin Alone on the Role of Pancreatic Islet Function, Insulin Resistance and Markers of Cardiovascular Risk in Patients With Prediabetes: Randomized Clinical Trial Completed NCT03004612 Phase 4 Metformin
15 Metformin in Co-morbid Diabetes or Prediabetes and Serious Mental Illness Completed NCT02167620 Phase 4 Metformin;Placebo
16 Comparative Effects of Antidiabetic Medications on Postprandial Hyperlipidemia, Free Fatty Acid Signaling, and Endothelial Dysfunction in Individuals With Prediabetes Completed NCT02104739 Phase 4 Exenatide;Saxagliptin;Exenatide extended-release (ER)
17 Effect of Anthocyanins on Metabolic Profiles in Subjects With Pre-diabetes: A Randomized, Double-blind, Placebo-controlled Study Completed NCT02689765 Phase 4
18 Diet and Exercise in Type 2 Diabetes and Prediabetes Completed NCT00928005 Phase 4
19 Effects of Metformin on Longevity Gene Expression and Inflammation and Prediabetic Individuals. A Placebo-controlled Trial Completed NCT01765946 Phase 4 Metformin;placebo
20 The Role of Incretins in the Pathogenesis of Fasting and Postprandial Glucose Metabolism in People With Impaired Fasting Glucose Completed NCT00364377 Phase 4 Sitagliptin
21 Improving Beta Cell Function in Mexican American Women With Prediabetes Completed NCT02488057 Phase 4 Liraglutide
22 The Assessment of the Effect of Metformin and Its Serum Concentration on the Concentration of Substances Associated With the Production of Nitric Oxide in Patients With Impaired Carbohydrate Metabolism Completed NCT03398356 Phase 4 Metformin
23 MetfoRmin and Its Effects on Myocardial Dimension and Left Ventricular Hypertrophy in Normotensive Patients With Coronary Artery Disease Completed NCT02226510 Phase 4 Metformin XL;Placebo
24 Effectiveness of the Translation of a Type 2 Diabetes Primary Prevention Program in Routine Context of Primary Heath Care Completed NCT01365013 Phase 4
25 Effects of Vitamin D on Beta Cell Function and Insulin Sensitivity in Pre-diabetes and Diabetes Mellitus Type 2 - EVIDENS Completed NCT01497132 Phase 4 Vitamin D3;Placebo
26 The Effect of Vitamin K Supplementation on Glucose Metabolism Completed NCT00960973 Phase 4 Menatetrenone;Placebo
27 Mechanisms of Action of Hydroxychloroquine in Reducing Risk of Type 2 Diabetes Completed NCT01326533 Phase 4 hydroxychloroquine
28 Mechanisms Underlying Metabolic Syndrome in Obesity Completed NCT00579813 Phase 4 Pioglitazone
29 The Effect of A-lipoic Acid (ALA) on Fatty Acid-induced Impairment of Glucose-stimulated Insulin Secretion Completed NCT01056497 Phase 4 alpha lipoic acid
30 Treatment With Sitagliptin Phosphate in Patients With Reactive Hypoglycemia Secondary to Dysinsulinism. A Controlled, Randomized, Double-blind, Clinical Trial Completed NCT00847080 Phase 4 Sitagliptin phosphate;Placebo
31 Postmarketing Clinical Study on AO-128 Completed NCT02287402 Phase 4 AO-128
32 High-dose Vitamin D Supplementation Reduces Inflammation and Improves Microcirculation in Patients With Diabetic Peripheral Neuropathy Completed NCT04377399 Phase 4 Vitamin D
33 Effect of Saxagliptin (DPP-4 Inhibitor) on Endothelial Progenitor Cells (EPCs) as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early Type 2 Diabetes Patients Completed NCT02024477 Phase 4 Saxagliptin;Placebo
34 Metformin in Longevity Study (MILES). Completed NCT02432287 Phase 4 Metformin;Placebo
35 A Randomized Pilot Study Evaluating Combination Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Plus Metformin Compared to Metformin Monotherapy and Placebo on Metabolic Abnormalities in Women With a Recent History of GDM Completed NCT01856907 Phase 4 Sitagliptin-Metformin;Metformin;Placebo pill
36 Hospital-based Diabetes Prevention Study in Korea: A Prospective, Multi-center, Randomized, Open-label Controlled Study Recruiting NCT02981121 Phase 4 Metformin
37 A Multi-center, Open-label, Randomized, 12-month, Parallel-group, Non-inferiority Study to Compare the Hemoglobin A1C Metabolism of Pitavastatin Therapy Versus Atorvastatin in Chinese Patients With Prediabetes and Hypertension Recruiting NCT03532620 Phase 4 Pitavastatin Calcium;Atorvastatin Calcium
38 Effect of Oral Supplementation With Curcumin on Insulin Sensitivity in Subjects With Prediabetes Recruiting NCT03917784 Phase 4 Curcumin;Starch
39 The Role of the Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose Metabolism Among African Americans: Pilot Study Recruiting NCT03938389 Phase 4 Sacubitril-Valsartan Tab 97-103 MG;Valsartan 160mg;Placebo Oral Tablet
40 Coronary Artery Disease Progression by iMap Intravascular Ultrasound Analysis in Patients With Prediabetes Recruiting NCT02744976 Phase 4 Metformin
41 MaasFlex: Double-Blind, Randomized, Phase IV, Mechanistic, Placebo-Controlled, Cross-Over, Single-Center Study to Evaluate the Effects of 2 Weeks Dapagliflozin Treatment on Nocturnal Substrate Oxidation, Glucose Metabolism and Muscle Mitochondrial Function in Individuals With Impaired Glucose Homeostasis Recruiting NCT03721874 Phase 4 Dapagliflozin 10mg;Placebo matching to Dapagliflozin 10 mg
42 Effect of Metadoxine on Oxidative Stress in Non-alcoholic Fatty Liver Disease Prediabetic Mexican Patients Recruiting NCT02051842 Phase 4 Metadoxine
43 Cardiovascular Effects of GLP-1 Receptor Activation Recruiting NCT03101930 Phase 4 Liraglutide;Sitagliptin;Placebos;Exendin (9-39)
44 Effect of Fasting Free Fatty Acids and Fasting Glucose on 1st and 2nd Phase Insulin Secretion Recruiting NCT03998709 Phase 4 Somatostatin;Insulin
45 GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response Recruiting NCT04387201 Phase 4 Dulaglutide;Cyanocobalamin
46 Role of Canagliflozin on Gene Expression and Function of CD34+ Endothelial Progenitor Cells and Renal Function in Patients With Type 2 Diabetes Recruiting NCT02964585 Phase 4 Canagliflozin;Placebo
47 A Multicentre, Open-labelled, Randomized, Controlled Study to Evaluate the Efficacy of Metformin in Preventing Diabetes in China. Active, not recruiting NCT03441750 Phase 4 metformin
48 Metformin Administration Effect Over Systemic Inflammation Serum Markers in HIV Positive Prediabetic Patients Active, not recruiting NCT03774108 Phase 4 Metformin Hydrochloride 850 MG
49 Effect of Administration of Berberine Versus Metformin on Glycemic Control, Insulin Sensitivity and Insulin Secretion in Patients With Prediabetes Active, not recruiting NCT03029390 Phase 4 Metformin
50 CSP #2002 - Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes (VA-IMPACT) Active, not recruiting NCT02915198 Phase 4 Metformin XR;Placebo

Search NIH Clinical Center for Prediabetes Syndrome

Cochrane evidence based reviews: prediabetic state

Sources

Genetic Tests for Prediabetes Syndrome

About this section
Sources

Anatomical Context for Prediabetes Syndrome

About this section

MalaCards organs/tissues related to Prediabetes Syndrome:

40
Heart, Testes, Liver, Endothelial, Kidney, Skin, Ovary
Sources

Publications for Prediabetes Syndrome

About this section

Articles related to Prediabetes Syndrome:

(show top 50) (show all 375)
# Title Authors PMID Year
1
Dietary supplements for prediabetes: A protocol for a systematic review and meta-analysis. 42
32443387 2020
2
Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. 42
32345662 2020
3
Relationship between multiple lifestyle behaviors and health-related quality of life among elderly individuals with prediabetes in rural communities in China: A STROBE-compliant article. 42
32282705 2020
4
Defects in insulin secretion and action in the pathogenesis of type 2 diabetes mellitus. 54 61
20425581 2010
5
Metabolic implications of dietary trans-fatty acids. 54 61
19584878 2009
6
Dietary fructose and the metabolic syndrome. 61 54
18301272 2008
7
Increasing the fat-to-carbohydrate ratio in a high-fat diet prevents the development of obesity but not a prediabetic state in rats. 54 61
17608620 2007
8
The DPP-4 inhibitor vildagliptin: robust glycaemic control in type 2 diabetes and beyond. 54 61
17877545 2007
9
Inhibition of MafA transcriptional activity and human insulin gene transcription by interleukin-1beta and mitogen-activated protein kinase kinase kinase in pancreatic islet beta cells. 54 61
17583797 2007
10
The metabolic syndrome and endothelial dysfunction: common highway to type 2 diabetes and CVD. 61 54
16879779 2006
11
Beta cell function, insulin resistance and plasma adiponectin concentrations are predictors for the change of postprandial glucose in non-diabetic subjects at risk for type 2 diabetes. 61 54
16673209 2006
12
Pathophysiology of prediabetes. 54 61
16570762 2005
13
Role of PPAR- gamma agonist thiazolidinediones in treatment of pre-diabetic and diabetic individuals: a cardiovascular perspective. 61 54
16248830 2005
14
Insulin resistance and metformin in polycystic ovary syndrome. 61 54
15262344 2004
15
Hyperglycemia as a cardiovascular risk factor. 61 54
14678859 2003
16
Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion. 61 54
14517163 2003
17
[Diabetes mellitus and the cerebrovascular disease]. 61 54
15775195 2003
18
Prediabetes in obese youth: a syndrome of impaired glucose tolerance, severe insulin resistance, and altered myocellular and abdominal fat partitioning. 61 54
14511928 2003
19
Insulin resistance, inflammation, and the prediabetic state. 61 54
12957323 2003
20
Insulin resistance--the new goal! 61 54
12795774 2003
21
Stress induced disturbances of the HPA axis: a pathway to Type 2 diabetes? 61 54
12601304 2003
22
Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. 61 54
12466345 2002
23
The relationship between insulin secretion, the insulin-like growth factor axis and growth in children with cystic fibrosis. 54 61
11940051 2002
24
Islet autoantibodies and insulin dependent diabetes mellitus in cystic fibrosis. 61 54
10714759 2000
25
Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. 61 54
10704163 2000
26
Defective function of the proteasome in autoimmunity: involvement of impaired NF-kappaB activation. 61 54
11467344 2000
27
Prevalence of diabetes-specific autoantibodies in patients at risk for adult onset diabetes mellitus. 54 61
9628241 1998
28
Central role of the adipocyte in insulin resistance. 54 61
10212835 1998
29
Characterization of the prediabetic state. 54 61
9324118 1997
30
Relationship of insulin resistance to microvascular dysfunction in subjects with fasting hyperglycaemia. 61 54
9049487 1997
31
Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. MRFIT Research Group. Multiple Risk Factor Intervention Trial. 54 61
8610702 1996
32
Insulin resistance and non-insulin-dependent diabetes mellitus: cellular and molecular mechanisms. 61 54
7900697 1995
33
The insulin-dependent patient: perceptions and preferences. 61 54
7600752 1995
34
Insulin resistance as the major cause of impaired glucose tolerance: a self-fulfilling prophesy? 54 61
7914964 1994
35
Insulin receptor isotype expression correlates with risk of non-insulin-dependent diabetes. 54 61
7681983 1993
36
Clinical studies with CE-inhibitors in diabetes. 61 54
2202631 1990
37
Pathobiology and Reversibility of Prediabetes in a Biracial Cohort (PROP-ABC) Study: design of lifestyle intervention. 61
32527719 2020
38
Diabetes and metabolic syndrome as risk factors for COVID-19. 61
32438331 2020
39
17β-estradiol ameliorates lipotoxicity-induced hepatic mitochondrial oxidative stress and insulin resistance. 61
32105829 2020
40
Loss of Thymine DNA Glycosylase Causes Dysregulation of Bile Acid Homeostasis and Hepatocellular Carcinoma. 61
32268085 2020
41
Early sensory neurophysiological changes in prediabetes. 61
31563156 2020
42
Mitochondrial Proton Leak Regulated by Cyclophilin D Elevates Insulin Secretion in Islets at Nonstimulatory Glucose Levels. 61
31740442 2020
43
Cacao extract enriched in polyphenols prevents endocrine-metabolic disturbances in a rat model of prediabetes triggered by a sucrose rich diet. 61
31580944 2020
44
Prevalence of Prediabetes and Diabetes Mellitus Type II in Bipolar Disorder. 61
32390884 2020
45
Trajectories of body mass index and waist circumference before the onset of diabetes among people with prediabetes. 61
31926761 2019
46
Liraglutide therapy in a prediabetic state: Rethinking the evidence. 61
31886752 2019
47
The effect of co supplementation of omega-3 and vitamin D on cardio metabolic risk factors and psychological distress in reproductive-aged women with prediabetes and hypovitaminosis D: a study protocol for a randomized controlled trial. 61
31888762 2019
48
Impaired Glucose Tolerance is Associated with Enhanced Platelet-Monocyte Aggregation in Short-Term High-Fat Diet-Fed Mice. 61
31703365 2019
49
Do Hospital Doctors Screen for Diabetes? 61
30296790 2019
50
The Novel Biomarkers in Diabetes. 61
31559772 2019
Sources

Variations for Prediabetes Syndrome

About this section
Sources

Expression for Prediabetes Syndrome

About this section
Search GEO for disease gene expression data for Prediabetes Syndrome.
Sources

Pathways for Prediabetes Syndrome

About this section

Pathways related to Prediabetes Syndrome according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 64
Show member pathways
 12.61 SLC2A4 LEP INS IL6 ADIPOQ
2
AMP-activated Protein Kinase (AMPK) Signaling 1
Show member pathways
 12.31 SLC2A4 PPARG LEP INS ADIPOQ
3
Glucose / Energy Metabolism 4
12.29 SLC2A4 PPARG INS HK1 GCG GAD1
5
Folate Metabolism 1
Show member pathways
 12.1 SERPINA3 INS IL6 CRP ALB
6
Peptide hormone metabolism 65
Show member pathways
 12.04 LEP INS GCG DPP4
7
Adipogenesis 1
11.75 SLC2A4 PPARG LEP INS IL6 ADIPOQ
8
Type II diabetes mellitus 36 1
Show member pathways
 11.69 SLC2A4 INS HK1 ADIPOQ
9
Adipocytokine signaling pathway 36
11.54 SLC2A4 LEP ADIPOQ
10
Incretin synthesis, secretion, and inactivation 65
Show member pathways
 11.42 LEP GCG DPP4
11
Mesenchymal Stem Cells and Lineage-specific Markers 64
11.41 SLC2A4 PPARG LEP INS IL6 ADIPOQ
12
Differentiation of white and brown adipocyte 1
11.01 PPARG LEP ADIPOQ
13
Cori Cycle 1
10.7 SLC2A4 INS HK1
14
Transcription factor regulation in adipogenesis 1
10.36 SLC2A4 PPARG LEP IL6 ADIPOQ
Sources

GO Terms for Prediabetes Syndrome

About this section

Cellular components related to Prediabetes Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 SERPINA3 LEP INS IL6 GCG DPP4
2 extracellular space GO:0005615 9.4 SERPINA3 MIR486-1 MIR454 MIR144 MIR126 LEP

Biological processes related to Prediabetes Syndrome according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.71 MIR126 LEP INS
2 response to nutrient GO:0007584 9.7 PPARG LEP ADIPOQ
3 regulation of insulin secretion GO:0050796 9.67 LEP GCG DPP4
4 positive regulation of MAPK cascade GO:0043410 9.67 MIR126 LEP INS IL6
5 response to nutrient levels GO:0031667 9.65 PPARG LEP ADIPOQ
6 cellular response to insulin stimulus GO:0032869 9.62 SLC2A4 PPARG LEP ADIPOQ
7 glucose metabolic process GO:0006006 9.61 LEP INS ADIPOQ
8 locomotory exploration behavior GO:0035641 9.55 GAD1 DPP4
9 negative regulation of blood vessel diameter GO:0097756 9.51 INS CRP
10 negative regulation of acute inflammatory response GO:0002674 9.46 PPARG INS
11 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.43 PPARG CRP ADIPOQ
12 positive regulation of fatty acid metabolic process GO:0045923 9.4 PPARG ADIPOQ
13 glucose homeostasis GO:0042593 9.35 SLC2A4 PPARG LEP INS ADIPOQ
14 negative regulation of lipid storage GO:0010888 9.33 LEP IL6 CRP
15 acute-phase response GO:0006953 8.92 SERPINA3 INS IL6 CRP

Molecular functions related to Prediabetes Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.56 PPARG INS HK1 GCG DPP4 CRP
2 hormone activity GO:0005179 8.92 LEP INS GCG ADIPOQ
Sources

Sources for Prediabetes Syndrome

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....